File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Article: Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review

TitleRepurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
Authors
KeywordsCanagliflozin
Cancer
Dapagliflozin
Drug repurposing
Sodium-glucose co-transporter 2 inhibitor
Treatment
Issue Date2021
PublisherSpringer New York LLC. The Journal's web site is located at https://www.springer.com/journal/11154
Citation
Reviews in Endocrine & Metabolic Disorders, 2021, v. 22 n. 4, p. 1121-1136 How to Cite?
AbstractDeveloped as an antidiabetic drug, recent evidence suggests that several sodium-glucose co-transporter 2 inhibitors (SGLT2i), especially canagliflozin and dapagliflozin, may exhibit in vitro and in vivo anticancer activities in selected cancer types, including an inhibition of tumor growth and induction of cell death. When used in combination with chemotherapy or radiotherapy, SGLT2i may offer possible synergistic effects in enhancing their treatment efficacy while alleviating associated side effects. Potential mechanisms include a reduction of glucose uptake into cancer cells, systemic glucose restriction, modulation of multiple signaling pathways, and regulation of different gene and protein expression. Furthermore, preliminary clinical findings have reported potential anticancer properties of canagliflozin and dapagliflozin in patients with liver and colon cancers respectively, with reference to decreases in their tumor marker levels. Given its general tolerability and routine use in diabetes management, SGLT2i may be a good candidate for drug repurposing in cancer treatment and as adjunct to conventional therapies. While current evidence reveals that only certain SGLT2i appear to be effective against selected cancer types, further studies are needed to explore the antitumor abilities of each SGLT2i in various cancers. Moreover, clinical trials are called for to evaluate the safety and feasibility of introducing SGLT2i in the treatment regimen of patients with specific cancers, and to identify the preferred route of drug administration for targeted delivery to selected tumor sites.
Persistent Identifierhttp://hdl.handle.net/10722/301914
ISSN
2020 Impact Factor: 6.514
2020 SCImago Journal Rankings: 1.916
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLau, KTK-
dc.contributor.authorNg, L-
dc.contributor.authorWong, JWH-
dc.contributor.authorLoong, HHF-
dc.contributor.authorChan, WWL-
dc.contributor.authorLee, CH-
dc.contributor.authorWong, CKH-
dc.date.accessioned2021-08-21T03:28:50Z-
dc.date.available2021-08-21T03:28:50Z-
dc.date.issued2021-
dc.identifier.citationReviews in Endocrine & Metabolic Disorders, 2021, v. 22 n. 4, p. 1121-1136-
dc.identifier.issn1389-9155-
dc.identifier.urihttp://hdl.handle.net/10722/301914-
dc.description.abstractDeveloped as an antidiabetic drug, recent evidence suggests that several sodium-glucose co-transporter 2 inhibitors (SGLT2i), especially canagliflozin and dapagliflozin, may exhibit in vitro and in vivo anticancer activities in selected cancer types, including an inhibition of tumor growth and induction of cell death. When used in combination with chemotherapy or radiotherapy, SGLT2i may offer possible synergistic effects in enhancing their treatment efficacy while alleviating associated side effects. Potential mechanisms include a reduction of glucose uptake into cancer cells, systemic glucose restriction, modulation of multiple signaling pathways, and regulation of different gene and protein expression. Furthermore, preliminary clinical findings have reported potential anticancer properties of canagliflozin and dapagliflozin in patients with liver and colon cancers respectively, with reference to decreases in their tumor marker levels. Given its general tolerability and routine use in diabetes management, SGLT2i may be a good candidate for drug repurposing in cancer treatment and as adjunct to conventional therapies. While current evidence reveals that only certain SGLT2i appear to be effective against selected cancer types, further studies are needed to explore the antitumor abilities of each SGLT2i in various cancers. Moreover, clinical trials are called for to evaluate the safety and feasibility of introducing SGLT2i in the treatment regimen of patients with specific cancers, and to identify the preferred route of drug administration for targeted delivery to selected tumor sites.-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at https://www.springer.com/journal/11154-
dc.relation.ispartofReviews in Endocrine & Metabolic Disorders-
dc.subjectCanagliflozin-
dc.subjectCancer-
dc.subjectDapagliflozin-
dc.subjectDrug repurposing-
dc.subjectSodium-glucose co-transporter 2 inhibitor-
dc.subjectTreatment-
dc.titleRepurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review-
dc.typeArticle-
dc.identifier.emailLau, KTK: kristytk@hku.hk-
dc.identifier.emailNg, L: luing@hku.hk-
dc.identifier.emailWong, JWH: jwhwong@hku.hk-
dc.identifier.emailChan, WWL: winglok@hku.hk-
dc.identifier.emailLee, CH: pchlee@hku.hk-
dc.identifier.emailWong, CKH: carlosho@hku.hk-
dc.identifier.authorityNg, L=rp02207-
dc.identifier.authorityWong, JWH=rp02363-
dc.identifier.authorityChan, WWL=rp02541-
dc.identifier.authorityLee, CH=rp02043-
dc.identifier.authorityWong, CKH=rp01931-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s11154-021-09675-9-
dc.identifier.pmid34272645-
dc.identifier.scopuseid_2-s2.0-85111118554-
dc.identifier.hkuros324202-
dc.identifier.volume22-
dc.identifier.issue4-
dc.identifier.spage1121-
dc.identifier.epage1136-
dc.identifier.isiWOS:000673178800001-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats